Hereditary Angioedema (HAE) Clinical Trial
Official title:
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
The main aim of this study is to compare the number of HAE attacks occuring in persons using lanadelumab with the number of HAE attacks before lanadelumab treatment was started. Data from participants who start the study after 1 March 2021, will be collected for 24 months; data from all other participants (who started the study before 1 March 2021) will be collected for 36 months. Participants will report information in a smartphone application at study start and for the next 3 months and then every 6 months until the study ends; data will also be collected by the study doctor during routine clinic visits
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02865720 -
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
|
Phase 3 | |
| Completed |
NCT04861090 -
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
|
||
| Recruiting |
NCT05489640 -
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
|
||
| Completed |
NCT02584959 -
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT01826916 -
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
|
Phase 2 | |
| Completed |
NCT04057131 -
FIRAZYR General Drug Use-Results Survey (Japan)
|
||
| Recruiting |
NCT05819775 -
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
|
Phase 3 | |
| Recruiting |
NCT05397431 -
A Survey of Lanadelumab in Participants With Hereditary Angioedema
|
||
| Completed |
NCT02741596 -
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
| Completed |
NCT02093923 -
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
|
Phase 1 | |
| Completed |
NCT01541423 -
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
|
||
| Completed |
NCT03845400 -
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
|
||
| Completed |
NCT02586805 -
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
| Completed |
NCT02052141 -
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT03888755 -
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
|
Phase 3 | |
| Recruiting |
NCT05147181 -
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
|
||
| Recruiting |
NCT05469789 -
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
|
||
| Completed |
NCT05460325 -
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
|
Phase 3 | |
| Completed |
NCT01095510 -
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
|
Phase 2 | |
| Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|